Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy
Authors:
- 30 July 2002
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 19 (8) , 655-660
Abstract
Aims Several reports have implicated nitric oxide (NO) in the angiogenic process. The assessment of NO stable end products, nitrite and nitrate (NOx), is commonly used as a measure of NO production in biological fluids. The aims of the study were to investigate NOx concentrations in the vitreous fluid of patients with proliferative diabetic retinopathy (PDR) and to evaluate the relationship between NOx and vascular endothelial growth factor (VEGF).Patients and methods Serum and vitreous fluid samples were obtained simultaneously at the time of vitreoretinal surgery from 23 patients with PDR, and 17 control non‐diabetic patients with non‐proliferative ocular disease. NOx was determined by using the Griess reaction and VEGF levels were assessed by ELISA.Results The intravitreous concentration of NOx was significantly elevated in patients with PDR in comparison with the control group (31.6 ± 2.96 µmol/l vs. 18 ± 2.46 µmol/l; P = 0.01). However, we did not detect any differences between NOx serum concentrations. We observed a correlation between serum and vitreous levels of NOx in diabetic patients (r = 0.79; P < 0.001), but not in the control group. Intravitreous levels of VEGF in patients with PDR were higher than those obtained in serum (1.42 ng/ml (0.12–7.62) vs. 0.12 ng/ml (0.03–0.42); P < 0.01). Vitreal levels of VEGF were strikingly higher in patients with PDR than in the control subjects (1.42 ng/ml (0.12–7.62) vs. 0.009 ng/ml (0.009–0.04); P < 0.001). No correlation between vitreal concentrations of NOx and VEGF was observed, either in diabetic patients or in the control group.Conclusions NOx and VEGF are increased but not related in the vitreous fluid of diabetic patients with PDR. Our results suggest that serum diffusion could play a significant role in explaining the increase of NOx. By contrast, intraocular production seems to be the main factor responsible for the intravitreous enhancement of VEGF.Diabet. Med. 19, 655–660 (2002)Keywords
This publication has 28 references indexed in Scilit:
- Determination of nitrite/nitrate in human biological material by the simple Griess reactionClinica Chimica Acta, 1998
- Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.Journal of Clinical Investigation, 1997
- Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathyDiabetologia, 1997
- Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.Journal of Clinical Investigation, 1997
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P.Journal of Clinical Investigation, 1994
- Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism.Proceedings of the National Academy of Sciences, 1994
- Biochemistry of Nitric Oxide and Its Redox-Activated FormsScience, 1992
- Inhibitors of nitric oxide synthase selectively reduce flow in tumour‐associated neovasculatureBritish Journal of Pharmacology, 1992
- Analysis of nitrate, nitrite, and [15N]nitrate in biological fluidsAnalytical Biochemistry, 1982